Abstract:Progesterone and AdipoQ Receptor 3 (PAQR3) is a member of the AdipoQ receptor. Our previous studies have found that PAQR3 plays a role as a candidate inhibitor in cardiac adenocarcinoma, breast cancer, gastric cancer and colorectal cancer, but the systematic analysis of PAQR3 in tumors is currently lacking. The objective of this study was to investigate the prognostic and therapeutic value of PAQR3 in 31 tumors. Through the analysis of TCGA, UALCAN, GEO, GEPIA2, TIMER, Kaplan–Meier plotter, TISIDB and other databases, it was found that the expression level of PAQR3 changed significantly in different tumor types, and the expression level of Neuroblastoma was very high. And the level of Prostate adenocarcinoma is low. In addition, the expression level of PAQR3 in Cholangiocarcinoma, Esophageal carcinoma, Head and neck squamous carcinoma, Liver Hepatocellular Carcinoma, Lung Adenocarcinoma and Lung squamous cell carcinoma was significantly higher than that in normal tissues. However, the expression level of PAQR3 in Breast Cancer, Kidney Renal Clear Cell Carcinoma, Kidney renal papillary cell carcinoma, Prostate Adenocarcinoma, Rectum Adenocarcinoma, Thyroid Cancer and Uterine Corpus Endometrial Carcinoma was lower than that in normal tissues. Subsequently, we explored the value of PAQR3 as a prognostic indicator of cancer. In Acute Myeloid Leukemia, Lower-grade Glioma and Glioblastoma, Pediatric Low-grade Gliomas, Kidney Chromophobe, and Thyroid Cancer, PAQR3 expression was positively correlated with OS and DSS, while in Rectum Adenocarcinoma, PAQR3 expression was negatively correlated with OS. PAQR3 high expression group Lower-grade Glioma and Glioblastoma, Pediatric Low-grade Gliomas, Uveal Melanoma, Kidney Chromophobe and DFI were positively correlated. PAQR3 can be used as a risk factor for the prognosis of multiple tumors. Then, we discussed the correlation between PAQR3 and immunology, and found that PAQR3 has a wide range of mutations in various tumor types, the most common mutation type is missense mutation, and common mutation types also include amplification, depth deletion, splicing, truncation and structural variation. Among the tumor samples with PAQR3 alterations, mutation occurred in all tumor samples except prostate adenocarcinoma and adrenal cortical carcinoma, head and neck squamous cell carcinoma, brain low-grade glioma, and kidney clear cell carcinoma, while esophageal adenocarcinoma had the highest total alteration frequency. PAQR3 was strongly associated with CNV in 18 tumors, particularly in Ovarian cancer, Lung squamous cell carcinoma, and Adenoid cystic carcinoma. On the other hand, PAQR3 has a higher SNV frequency in Uterine Corpus Endometrial Carcinoma, Skin Cutaneous Melanoma and Lung Adenocarcinoma, among which Uterine Corpus Endometrial Carcinoma has the highest SNV frequency. These results showed that PAQR3 expression levels were significantly correlated with tumor mutation load, microsatellite instability, neoantigens, and purity. In summary, PAQR3 can affect the tumor microenvironment and has potential for chemotherapy. Finally, we investigated the role of PAQR3 in tumor resistance and found that the expression of PAQR3 affects the efficacy of multiple chemotherapy drugs. Based on these studies, we found that PAQR3 plays an important role in cancer and has potential in tumor diagnosis and prognosis.

PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy

PAQR3 Controls Autophagy by Integrating AMPK Signaling to Enhance ATG14L-associated PI3K Activity.

Two-layer Regulation of PAQR3 on ATG14-linked Class III PtdIns3K Activation Upon Glucose Starvation

PAQR3 Inhibits Non-small Cell Lung Cancer Growth by Regulating the NF-κB/p53/Bax Axis

PAQR3 Augments Amino Acid Deprivation-Induced Autophagy by Inhibiting Mtorc1 Signaling.

PAQR3 Modulates H3K4 Trimethylation by Spatial Modulation of the Regulatory Subunits of COMPASS-like Complexes in Mammalian Cells.

PAQR3 enhances Twist1 degradation to suppress epithelial–mesenchymal transition and metastasis of gastric cancer cells

AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.

High Expression of Rabl3 is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer Via Repression of MAPK8/9/10-Mediated Autophagy

High Expression of Rab-like 3 (rabl3) is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer Via Repression of MAPK8/9/10-Mediated Autophagy

PAQR5 inhibits the growth and metastasis of clear cell renal cell carcinoma by suppressing the JAK/STAT3 signaling pathway

The Emerging Roles and Mechanisms of PAQR3 in Human Cancer: Pathophysiology and Therapeutic Implications

PAQR3 Plays a Suppressive Role in the Tumorigenesis of Colorectal Cancers.

Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer

Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin‐dependent kinases regulatory subunit 2

Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3

CDKL3 Promotes Non-small Cell Lung Cancer by Suppressing Autophagy Via Activation of PI3K/Akt/mTOR Pathway.

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy

PRKCI Negatively Regulates Autophagy Via PIK3CA/AKT–MTOR Signaling

[Expression and Clinical Significance of Progesterone and Adiponectin Receptor Family Member 3 in Lung Cancer].